Drug Profile
Research programme: human placental growth factor - Oxurion
Latest Information Update: 11 Sep 2018
Price :
$50
*
At a glance
- Originator University of Leuven
- Developer Oxurion
- Class Growth factors
- Mechanism of Action Intercellular signalling peptide and protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ischaemic heart disorders; Peripheral arterial occlusive disorders; Wounds
Most Recent Events
- 10 Sep 2018 Thrombogenics is now called Oxurion
- 04 Nov 2017 No recent reports of development identified for preclinical development in Ischaemic-heart-disorders in Europe (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Peripheral-arterial-occlusive-disorders in Europe (Parenteral)